Last reviewed · How we verify
Dexmedetomidine 1
Dexmedetomidine 1 is a Alpha-2 adrenergic receptor agonist Small molecule drug developed by National Cancer Institute, Egypt. It is currently FDA-approved for Sedation of initially intubated and mechanically ventilated patients in intensive care units, Sedation and analgesia for procedural use. Also known as: Early Dexmedetomidine, Dex,Dexmedetomidine.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation of initially intubated and mechanically ventilated patients in intensive care units, Sedation and analgesia for procedural use.
At a glance
| Generic name | Dexmedetomidine 1 |
|---|---|
| Also known as | Early Dexmedetomidine, Dex,Dexmedetomidine |
| Sponsor | National Cancer Institute, Egypt |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Sedation |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, particularly in the locus coeruleus and other brainstem regions, leading to decreased norepinephrine release and reduced neuronal firing. This results in a unique sedative state characterized by maintained airway reflexes and the ability to be aroused, along with analgesic and anxiolytic effects. The drug is commonly used for sedation in intensive care and procedural settings.
Approved indications
- Sedation of initially intubated and mechanically ventilated patients in intensive care units
- Sedation and analgesia for procedural use
Common side effects
- Hypotension
- Bradycardia
- Hypertension (transient, initial)
- Dry mouth
- Rebound hypertension on discontinuation
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Continuous Epidural With Dexmedetomidine Adjuvant in Gynecologic Laparotomy (PHASE4)
- Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome (PHASE4)
- Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine (PHASE4)
- Dexmedotomidine for Acute Pain Control in Patients With Multiple Rib FracturesRandomized Controlled Trial (PHASE4)
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Cardiac Index and General Anesthesia Without Opioid. (PHASE2, PHASE3)
- Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine 1 CI brief — competitive landscape report
- Dexmedetomidine 1 updates RSS · CI watch RSS
- National Cancer Institute, Egypt portfolio CI
Frequently asked questions about Dexmedetomidine 1
What is Dexmedetomidine 1?
How does Dexmedetomidine 1 work?
What is Dexmedetomidine 1 used for?
Who makes Dexmedetomidine 1?
Is Dexmedetomidine 1 also known as anything else?
What drug class is Dexmedetomidine 1 in?
What development phase is Dexmedetomidine 1 in?
What are the side effects of Dexmedetomidine 1?
What does Dexmedetomidine 1 target?
Related
- Drug class: All Alpha-2 adrenergic receptor agonist drugs
- Target: All drugs targeting Alpha-2 adrenergic receptor
- Manufacturer: National Cancer Institute, Egypt — full pipeline
- Therapeutic area: All drugs in Anesthesia/Sedation
- Indication: Drugs for Sedation of initially intubated and mechanically ventilated patients in intensive care units
- Indication: Drugs for Sedation and analgesia for procedural use
- Also known as: Early Dexmedetomidine, Dex,Dexmedetomidine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing